Launch of AI Formulation Supply in Norway
Wins IZAAZ and SMK Tenders in the Netherlands
Exclusive Supply Rights for Omriclo Secured in Denmark
Active Utilization of Established Local Sales Networks

Celltrion’s new product lineup is rapidly expanding its sales by winning successive pharmaceutical tenders in major European countries such as Norway, the Netherlands, and Denmark. The company is leveraging its direct sales network and tendering system, built through existing autoimmune disease treatments, to broaden market entry for its new products beyond the EU5 (Germany, France, Italy, Spain, and the United Kingdom).

Celltrion 'Aptozma' product image. Celltrion

Celltrion 'Aptozma' product image. Celltrion

View original image

On October 1, Celltrion announced that its autoimmune disease treatment 'Aptozyme' (ingredient: tocilizumab) won the national tender in Norway and has been supplying both pre-filled syringe (PFS) and auto-injector (AI) formulations since early this year. The contract period is two years. During this period, Celltrion expects to secure an average market share of around 85% in the local tocilizumab market.


Sales of Aptozyme are also expanding in Finland. In the retail market centered on subcutaneous (SC) formulations, the product achieved a 42% market share as of June this year. Additionally, the intravenous (IV) formulation recently won the tender for the eastern region of Finland.


In the Netherlands, Celltrion secured supply volume by focusing on major hospitals and pharmacy purchasing consortia. The company won tenders with the local pharmaceutical procurement group (IZAAZ), which consists of seven university hospitals, and musculoskeletal and rheumatology specialty hospitals (SMK), and has been supplying Aptozyme since March this year.


In the second quarter of this year, Celltrion also won tenders from the southeastern pharmaceutical procurement consortium (ICZON) and the joint purchasing network for hospital pharmaceuticals (ZRIG). According to Celltrion, the secured supply volume through these contracts accounts for approximately 58% of the tocilizumab market in the Netherlands.


The direct sales network established through existing products is seen as contributing to the successful market entry of new items. In the Netherlands, Celltrion has directly sold autoimmune disease treatments such as Remsima and Yuflyma, building a strong network with healthcare professionals and tendering agencies.


Other new products have also achieved notable tender results in Northern Europe. The chronic spontaneous urticaria and allergic asthma treatment 'Omriclo' (ingredient: omalizumab) secured exclusive supply rights in Denmark and recently managed to extend its supply contract. Celltrion expects to maintain a market share of over 98% in the Danish omalizumab market by the end of the year.


The bone disease treatment 'Ocentbelt' (ingredient: denosumab) has been awarded sole supplier status in the national tenders of Norway and Denmark and is scheduled to begin supply this month.


Looking ahead, Celltrion plans to expand its product tendering efforts not only within the EU5 but also in Northern Europe and other smaller European countries to further broaden its sales base.



Baek Seungdoo, Head of Celltrion’s Northern Europe branch, stated, "We are continuously achieving tender results for new product lines in key Northern European countries and have secured exclusive supply status in some regions. We will focus on converting these tender wins into actual sales and strengthen our sales and marketing activities to drive prescription growth in the retail market as well."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing